<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on July 28, 2020</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT02612701</url>
  </required_header>
  <id_info>
    <org_study_id>Pro00041957</org_study_id>
    <nct_id>NCT02612701</nct_id>
  </id_info>
  <brief_title>E-Cigarette Aerosol, Conventional Cigarette Smoke, and Myocardial Perfusion</brief_title>
  <official_title>E-Cigarette Aerosol, Conventional Cigarette Smoke, and Myocardial Perfusion</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Cedars-Sinai Medical Center</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Cedars-Sinai Medical Center</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      E-cigarettes deliver nicotine by creating an aerosol of ultrafine particles. Many questions
      remain about the size and composition and especially about the potential toxicity of these
      particles. Thus, a key unanswered question—and the research question proposed—is whether
      e-cigarette aerosol triggers the same acute impairment in coronary microvessel function as
      does conventional cigarette smoke, which delivers a very well-defined exposure to fine
      particles and many fold greater exposure to toxic (combustion) products including volatile
      organic compounds (such as acrolein) that have been implicated in the pathogenesis of
      tobacco-related coronary disease.

      Because the effects of nicotine on the human coronary microcirculation remain incompletely
      defined—with multiple potential vasodilator and vasoconstrictor actions each of which may
      vary by dose—we will determine the comparative effects of conventional cigarette smoke
      against e-cigarette aerosol with no nicotine, with low-dose nicotine, and with high-dose
      nicotine.
    </textblock>
  </brief_summary>
  <overall_status>Active, not recruiting</overall_status>
  <start_date>October 2015</start_date>
  <completion_date type="Anticipated">October 2020</completion_date>
  <primary_completion_date type="Actual">October 1, 2018</primary_completion_date>
  <phase>N/A</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Non-Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Other</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Myocardial Perfusion (change in microvascular flux rate from baseline at 30 minutes)</measure>
    <time_frame>Baseline and 30 minutes after smoking</time_frame>
    <description>Myocardial contrast echocardiography will be used to measure regional myocardial perfusion - microvascular flux rate</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Myocardial Perfusion (change in capillary blood volume from baseline at 30 minutes)</measure>
    <time_frame>Baseline and 30 minutes after smoking</time_frame>
    <description>Myocardial contrast echocardiography will be used to measure regional myocardial perfusion - capillary blood volume</description>
  </primary_outcome>
  <number_of_arms>4</number_of_arms>
  <enrollment type="Anticipated">20</enrollment>
  <condition>Coronary Artery Disease</condition>
  <condition>Myocardial Perfusion</condition>
  <arm_group>
    <arm_group_label>Cigarettes</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Healthy chronic dual cigarette and e-cigarette smokers will undergo myocardial contrast echocardiography before and after smoking two standard cigarettes</description>
  </arm_group>
  <arm_group>
    <arm_group_label>E-cigarettes (nicotine free e-liquid)</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Healthy chronic dual cigarette and e-cigarette smokers will undergo myocardial contrast echocardiography before and after smoking nicotine free e-cigarette liquid.</description>
  </arm_group>
  <arm_group>
    <arm_group_label>E-cigarettes (low nicotine e-liquid)</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Healthy chronic dual cigarette and e-cigarette smokers will undergo myocardial contrast echocardiography before and after smoking low concentration(4-6 mg/mL) e-cigarette liquid.</description>
  </arm_group>
  <arm_group>
    <arm_group_label>E-cigarettes (high nicotine e-liquid)</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Healthy chronic dual cigarette and e-cigarette smokers will undergo myocardial contrast echocardiography before and after smoking high concentration (18-24 mg/mL) e-cigarette liquid.</description>
  </arm_group>
  <intervention>
    <intervention_type>Other</intervention_type>
    <intervention_name>Cigarettes</intervention_name>
    <description>Subjects will smoke a standard cigarette (yield: tar 12 mg, nicotine 1 mg)</description>
    <arm_group_label>Cigarettes</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Other</intervention_type>
    <intervention_name>E-cigarettes (nicotine free e-liquid)</intervention_name>
    <description>Subjects will smoke nicotine free e-liquid with an e-cigarette.</description>
    <arm_group_label>E-cigarettes (nicotine free e-liquid)</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Other</intervention_type>
    <intervention_name>E-cigarettes (low nicotine e-liquid)</intervention_name>
    <description>Subjects will smoke low nicotine (4-6 mg/mL) e-liquid with an e-cigarette.</description>
    <arm_group_label>E-cigarettes (low nicotine e-liquid)</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Other</intervention_type>
    <intervention_name>E-cigarettes (high nicotine e-liquid)</intervention_name>
    <description>Subjects will smoke low nicotine (18-24 mg/mL) e-liquid with an e-cigarette.</description>
    <arm_group_label>E-cigarettes (high nicotine e-liquid)</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  Age 18-49

          -  Regular cigarette smoker defined as at least 1 pack year and ≥ 5/day

          -  E-cigarette smoker defined as ≥ 1/week in the last 6 months.

        Exclusion Criteria:

          -  Sub-optimal echocardiography images as determined by the sonographer and/or
             investigators.

          -  History of cardiopulmonary (including asthma or use of inhalers),

          -  History of diabetes or dyslipidemia

          -  History of psychiatric illness

          -  Blood Pressure &gt; 140/90

          -  Body Mass Index ≤ 18.5 or ≥ 30 kg•m2

          -  Evidence of any of the above by physical examination, Electrocardiogram (ECG) or
             echocardiogram

          -  Resting Heart Rate &gt; 100 beats/min

          -  Cardiac rhythm disorder, specifically: rhythm other than sinus, Supraventricular
             Tachycardia (SVT), atrial fibrillation, ventricular tachycardia

          -  Use of prescription medication except oral contraceptive pills

          -  History of illicit drug use (self-stated)

          -  Pregnant

          -  Any other condition(s) deemed by the physician investigators that put subjects at risk
             for participating in the study
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>49 Years</maximum_age>
    <healthy_volunteers>Accepts Healthy Volunteers</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Florian Rader, MD</last_name>
    <role>Principal Investigator</role>
    <affiliation>Cedars-Sinai Medical Center</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>Cedars-Sinai Medical Center</name>
      <address>
        <city>Los Angeles</city>
        <state>California</state>
        <zip>90048</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>United States</country>
  </location_countries>
  <verification_date>November 2019</verification_date>
  <study_first_submitted>November 17, 2015</study_first_submitted>
  <study_first_submitted_qc>November 20, 2015</study_first_submitted_qc>
  <study_first_posted type="Estimate">November 24, 2015</study_first_posted>
  <last_update_submitted>November 1, 2019</last_update_submitted>
  <last_update_submitted_qc>November 1, 2019</last_update_submitted_qc>
  <last_update_posted type="Actual">November 5, 2019</last_update_posted>
  <responsible_party>
    <responsible_party_type>Principal Investigator</responsible_party_type>
    <investigator_affiliation>Cedars-Sinai Medical Center</investigator_affiliation>
    <investigator_full_name>Florian Rader</investigator_full_name>
    <investigator_title>M.D, M.Sc.</investigator_title>
  </responsible_party>
  <keyword>Myocardial perfusion</keyword>
  <keyword>Electronic cigarettes</keyword>
  <keyword>Cigarettes</keyword>
  <keyword>Cigarette smoking</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Coronary Artery Disease</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Nicotine</mesh_term>
  </intervention_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

